| Name | Title | Contact Details |
|---|
MapLight Therapeutics is developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders. Today, there are few therapeutic options for people living with conditions such as schizophrenia, Alzheimer`s disease, Parkinson`s, and autism spectrum disorder. Available treatments are limited by modest efficacy and significant side effects. MapLight is committed to redefining this standard of care. The company`s unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and treat those circuits with effective, safe therapeutics. MapLight was founded in 2019 by a team of renowned neuroscientists who led the discovery of the two groundbreaking technologies, optogenetics and STARmap.
Dynotx.com provides cutting-edge sales and marketing tools for small and medium-sized businesses. Their services include web design, social media management, advertising, and SEO optimization. They aim to help businesses grow and succeed online by prov...
Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.
AmProx is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmaTech is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.